6,789 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Purchased by FORA Capital LLC

FORA Capital LLC acquired a new position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 6,789 shares of the company’s stock, valued at approximately $399,000.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Apogee Therapeutics by 60.7% during the first quarter. Vanguard Group Inc. now owns 1,868,666 shares of the company’s stock valued at $124,173,000 after acquiring an additional 705,795 shares during the period. Point72 DIFC Ltd acquired a new position in Apogee Therapeutics in the 2nd quarter worth approximately $660,000. XTX Topco Ltd purchased a new position in Apogee Therapeutics during the 2nd quarter worth approximately $706,000. Victory Capital Management Inc. raised its stake in Apogee Therapeutics by 56.8% during the 2nd quarter. Victory Capital Management Inc. now owns 156,266 shares of the company’s stock valued at $6,149,000 after purchasing an additional 56,607 shares during the period. Finally, Waypoint Capital Advisors LLC purchased a new stake in shares of Apogee Therapeutics in the third quarter valued at $36,835,000. 79.04% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $59.22, for a total transaction of $888,300.00. Following the completion of the sale, the chief executive officer now owns 1,339,487 shares of the company’s stock, valued at $79,324,420.14. This represents a 1.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Carl Dambkowski sold 6,665 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $47.56, for a total transaction of $316,987.40. Following the sale, the insider now directly owns 280,793 shares of the company’s stock, valued at approximately $13,354,515.08. This represents a 2.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 114,995 shares of company stock valued at $6,128,295 over the last three months. 36.10% of the stock is currently owned by insiders.

Apogee Therapeutics Stock Up 1.0 %

Shares of APGE opened at $45.15 on Friday. Apogee Therapeutics, Inc. has a 12 month low of $17.17 and a 12 month high of $72.29. The company’s fifty day moving average is $53.67 and its 200-day moving average is $48.51. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of -18.66 and a beta of 2.93.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Canaccord Genuity Group started coverage on Apogee Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $89.00 price target on the stock. Canaccord Genuity Group initiated coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $87.00 price target on shares of Apogee Therapeutics in a research report on Tuesday, November 12th. Finally, Guggenheim raised their price target on shares of Apogee Therapeutics from $95.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Apogee Therapeutics has a consensus rating of “Buy” and a consensus target price of $83.50.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.